Clinical Efficacy of Biosimilar Switch of Adalimumab for Management of Uveitis

References

• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160.
   PubMed Web of Science ®Google Scholar
• Angeles-Han ST, Lo MS, Henderson LA, et al. Childhood arthritis and rheumatology research alliance consensus treatment plans for juvenile idiopathic arthritis-associated and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken). 2019;71(4):482–491. doi:10.1002/acr.23610.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–1117. doi:10.1136/annrheumdis-2018-213131.
   PubMed Web of Science ®Google Scholar
• Davio K. 2018. Accessed 2021 October 10. https://www.centerforbiosimilars.com/view/nhs-prepares-for-october-2018-arrival-of-biosimilar-adalimumab.
   Google Scholar
• Bellinvia S, Cummings JRF, Ardern-Jones MR, Edwards CJ. Adalimumab biosimilars in Europe: an overview of the clinical evidence. BioDrugs. 2019;33(3):241–253. doi:10.1007/s40259-019-00355-4.
   PubMed Web of Science ®Google Scholar
• Adalimumab Biosimilars Ready To Enter Australian, Korean, Japanese and European Markets Jdsupra.com. 2021.Accessed 2022 February 15. https://www.jdsupra.com/legalnews/adalimumab-biosimilars-ready-to-enter-5277645/.
   Google Scholar
• McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs. 2011;3(2):209–217. doi:10.4161/mabs.3.2.15005.
   PubMed Web of Science ®Google Scholar
• Azevedo V, Dörner T, Strohal R, et al. Biosimilars: considerations for clinical practice. Considerations Med. 2017;1(1):13–18. doi:10.1136/conmed-2017-100005.
   Google Scholar
• Fleischmann R, Jairath V, Mysler E, Nicholls D, Declerck P. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7(1):35–64. doi:10.1007/s40744-019-00190-7.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900. doi:10.1136/rmdopen-2019-000900.
   PubMed Web of Science ®Google Scholar
• Renton WD, Leveret H, Guly C, Smee H, Leveret J, Ramanan AV. Same but different? A thematic analysis on Adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2019;17(1):67. doi:10.1186/s12969-019-0366-x.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. The role of biosimilars in uveitis: long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors. Front Pharmacol. 2019;10:1468. doi:10.3389/fphar.2019.01468.
   PubMed Web of Science ®Google Scholar
• Ulu K, Demir F, Coşkuner T, Ş Ç, Sözeri B. POS0630 Comparison of the efficacy and safety of original and biosimilar adalimumab molecules in childhood rheumatic diseases. Ann Rheum Dis. 2021;80(Suppl 1):553. doi:10.1136/annrheumdis-2021-eular.2979.
   Google Scholar
• Sota J, Gentileschi S, Vitale A, et al. Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience. Asia Pac J Ophthalmol (Phila). 2021;10(4):360–365. doi:10.1097/APO.0000000000000380.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ebrahimiadib N, Hedayatfar A, Hosseini M, Zarei M, Anjidani N. Efficacy of biosimilar adalimumab in the treatment of Behçet’s uveitis. Ocul Immunol Inflamm. 2022;30(6):14961500. doi:10.1080/09273948.2021.1900276.
   Web of Science ®Google Scholar
• Demirkan FG, Ulu K, Öztürk K, et al. Toward the integration of biosimilars into pediatric rheumatology: Adalimumab ABP 501 experience of PeRA research group. Expert Opin Biol Ther. 2021;22(6)1–6.
   Web of Science ®Google Scholar
• Loft N, Egeberg A, Rasmussen MK, et al. Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis. JAMA Dermatol. 2021;157(6):676–683. doi:10.1001/jamadermatol.2021.0221.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609. doi:10.1080/03007995.2018.1560221.
   PubMed Web of Science ®Google Scholar
• Hughes DA, Culeddu G, Plumpton CO, et al. Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis. Ophthalmology. 2019;126(3):415–424. doi:10.1016/j.ophtha.2018.09.043.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
   PubMed Web of Science ®Google Scholar
• Moorkens E, Godman B, Huys I, et al. The expiry of Humira(®) market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2020;11:591134. doi:10.3389/fphar.2020.591134.
   PubMed Web of Science ®Google Scholar